News

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]

Part B of the 2-part study will have patients previously on placebo receive SRP-9001 for an additional 52 weeks.

The 2022 MDA National Ambassador and patient with Bethlem myopathy spoke to the importance of including the patient perspective at medical meetings to improve the care paradigm in neuromuscular disorders. [WATCH TIME: 3 minutes]

After being originally approved as a generic medication in 1996, a new transdermal formulation of donepezil is expected to be available for patients with Alzheimer disease in the fall of 2022.

Individuals on ravulizumab demonstrated statistically significant changes in the primary end point of MG-ADL and in secondary end points such as Quantitative Myasthenia Gravis total score.

At 97 weeks, avalglucosidase alfa showed continued benefit on measures such as forced vital capacity and 6-minute walk test distance and was successful for patients who switched off algucosidase alfa.

Data from the phase 2 NURTURE study of nusinersen (Spinraza; Biogen) suggest that long-term treatment with the agent is beneficial, and point to the importance of newborn screening and early treatment for spinal muscular atrophy.

At months 6, 9, and 12 of treatment with daridorexant—which was recently FDA-approved for insomnia—patients improved on several sleep measures, including subjective total sleep time and daytime functioning.

The neurologist and assistant professor at the University of Toronto provided insight on the clinical use of retinal imaging tools like RetiSpec and the need for further validation of these approaches in Alzheimer disease. [WATCH TIME: 2 minutes]

Here's what is coming soon to NeurologyLive®.

The neurologist and assistant professor at the University of Toronto discussed data presented at CTAD 2021 on RetiSpec, a retinal imaging tool that predicts brain amyloid status. [WATCH TIME: 3 minutes]

Speaking on his own presentation on economic burden in MS, Bruce Bebo, PhD, further shared his thoughts on areas of unmet need and the potential relationship of Epstein-Barr virus and MS.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Most of the 52 cognitive resilience proteins were found to be specific for cognitive decline and about 30% may provide resilience for both cognitive and noncognitive AD phenotypes.

A systematic literature review of randomized controlled trials in neuromyelitis optica spectrum disorder was performed, with 7 studies identified and 2 used in analyses.

Neurology News Network for the week ending March 12, 2022. [WATCH TIME: 4 minutes]

Investigators noted the long-term cost-effectiveness and safety of this approach, as it does not require the regular use of disease-modifying therapies.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 11, 2022.

The founding chair of the department of brain health at the University of Nevada Las Vegas provided background on how a newly funded NIH grant will contribute to translational neuroscience research infrastructure. [WATCH TIME: 3 minutes]

The Muscular Dystrophy Association's annual meeting will take place in-person and virtually in Nashville, Tennessee, on March 13-16, with more than 950 in-person attendees and 130 presenters.

The assistant professor of neurology at the University of Pennsylvania discussed how 7T MRI features of newly developed MS lesions can predict the development of chronic active lesions. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Seema Khosla, MD, FCCP, FAASM. [LISTEN TIME: 29 minutes]

The study had a goal to provide a personalized treatment approach, including ASM dosage changes to prevent seizure worsening and optimizing the balance of outcomes for mothers and children.

Patients with chronic migraine on 60-mg once-daily and 30-mg twice-daily atogepant demonstrated reductions of 6.88 and 7.46 monthly migraine days, respectively, over a 12-week period.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]

Data from the 24-week, multicenter LibraTN trial are expected to be reported in the first half of 2024.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research offered her insight into improving the recognition of autoimmune encephalitis. [WATCH TIME: 2 minutes]

Bruce Bebo, PhD, outlined findings from a recent analysis presented at ACTRIMS Forum 2022, with investigators concluding costs associated with the disease have previously been underestimated.

The cohort study was conducted in Taiwan, with investigators also observing changes over time in the influence of sex, stroke type, and copayment exemption type of rehabilitation utilization.

In the EVOKE study (NCT02924129), the spinal cord stimulation system demonstrated superior pain relief compared to open-loop SCS at 12 months with no increase in pain medication.